Literature DB >> 20116225

Limitations in doxorubicin production from Streptomyces peucetius.

Sailesh Malla1, Narayan Prasad Niraula, Bijay Singh, Kwangkyoung Liou, Jae Kyung Sohng.   

Abstract

Doxorubicin (DXR), produced by Streptomyces peucetius ATCC 27952, exhibits potent antitumor activity against various cancer cell lines. Considerable time has lapsed since the biosynthesis of DXR and its overproduction was first summarized. Based on biosynthetic studies and product analysis, various factors affecting its production by the parental strain, S. peucetius ATCC 27952, are reviewed to better circumvent any bottlenecks in DXR production, thereby providing ideas to genetically engineered industrial strains of S. peucetius. Copyright 2009 Elsevier GmbH. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20116225     DOI： 10.1016/j.micres.2009.11.006

Source DB:  PubMed          Journal:  Microbiol Res        ISSN： 0944-5013            Impact factor:   5.415


  14 in total

1.  Sirt3 attenuates doxorubicin-induced cardiac hypertrophy and mitochondrial dysfunction via suppression of Bnip3.

Authors:  Qiong Du; Bin Zhu; Qing Zhai; Bo Yu
Journal:  Am J Transl Res       Date:  2017-07-15       Impact factor: 4.060

2.  Sirt3 protects mitochondrial DNA damage and blocks the development of doxorubicin-induced cardiomyopathy in mice.

Authors:  Vinodkumar B Pillai; Samik Bindu; Will Sharp; Yong Hu Fang; Gene Kim; Madhu Gupta; Sadhana Samant; Mahesh P Gupta
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-02-12       Impact factor: 4.733

Review 3.  Anticancer effects of the microbiome and its products.

Authors:  Laurence Zitvogel; Romain Daillère; María Paula Roberti; Bertrand Routy; Guido Kroemer
Journal:  Nat Rev Microbiol       Date:  2017-05-22       Impact factor: 60.633

4.  Towards potent but less toxic nanopharmaceuticals - lipoic acid bioconjugates of ultrasmall gold nanoparticles with an anticancer drug and addressing unit.

Authors:  Maciej Dzwonek; Dominika Załubiniak; Piotr Piątek; Grzegorz Cichowicz; Sylwia Męczynska-Wielgosz; Tomasz Stępkowski; Marcin Kruszewski; Agnieszka Więckowska; Renata Bilewicz
Journal:  RSC Adv       Date:  2018-04-19       Impact factor: 4.036

5.  Pathway Engineering of Anthracyclines: Blazing Trails in Natural Product Glycodiversification.

Authors:  Katelyn V Brown; Benjamin Nji Wandi; Mikko Metsä-Ketelä; S Eric Nybo
Journal:  J Org Chem       Date:  2020-09-22       Impact factor: 4.354

6.  Intestinal bacteria are necessary for doxorubicin-induced intestinal damage but not for doxorubicin-induced apoptosis.

Authors:  Rachael J Rigby; Jacquelyn Carr; Kelly Orgel; Stephanie L King; P Kay Lund; Christopher M Dekaney
Journal:  Gut Microbes       Date:  2016-07-26

7.  Insights into the transposable mobilome of Paracoccus spp. (Alphaproteobacteria).

Authors:  Lukasz Dziewit; Jadwiga Baj; Magdalena Szuplewska; Anna Maj; Mateusz Tabin; Anna Czyzkowska; Grazyna Skrzypczyk; Marcin Adamczuk; Tomasz Sitarek; Piotr Stawinski; Agnieszka Tudek; Katarzyna Wanasz; Ewa Wardal; Ewa Piechucka; Dariusz Bartosik
Journal:  PLoS One       Date:  2012-02-16       Impact factor: 3.240

8.  Detoxified pneumolysin derivative ΔA146Ply inhibits autophagy and induces apoptosis in acute myeloid leukemia cells by activating mTOR signaling.

Authors:  Tao Zhu; Hong Zhang; Sijie Li; Kaifeng Wu; Yibing Yin; Xuemei Zhang
Journal:  Exp Mol Med       Date:  2022-05-10       Impact factor: 12.153

Review 9.  Focused Review: Cytotoxic and Antioxidant Potentials of Mangrove-Derived Streptomyces.

Authors:  Hooi-Leng Ser; Loh Teng-Hern Tan; Jodi Woan-Fei Law; Kok-Gan Chan; Acharaporn Duangjai; Surasak Saokaew; Priyia Pusparajah; Nurul-Syakima Ab Mutalib; Tahir Mehmood Khan; Bey-Hing Goh; Learn-Han Lee
Journal:  Front Microbiol       Date:  2017-11-01       Impact factor: 5.640

10.  RFX1 participates in doxorubicin-induced hepatitis B virus reactivation.

Authors:  Jie Wang; Junqiao Jia; Ran Chen; Shanlong Ding; Qiang Xu; Ting Zhang; Xiangmei Chen; Shuang Liu; Fengmin Lu
Journal:  Cancer Med       Date:  2018-03-30       Impact factor: 4.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.